Altimmune To Report Third Quarter 2026 Financial Results And Provide Business Update On November 12, 2026
Altimmune management will host a conference call at 8:30 a.m. ET on November 12 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website.
Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on the Investor Relations website shortly after the call for up to three months.
About Altimmune
Altimmune is a biopharmaceutical company developing pemvidutide for patients with serious liver diseases. Pemvidutide, a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio, is in late-stage clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), recently showed robust results in the RECLAIM Phase 2 trial in alcohol use disorder (AUD) and is being studied in alcohol-associated liver disease (ALD). For more information, please visit .
Follow @AltimmuneInc on X
Investor Contact:
Luis Sanay, CFA
...
Media Contact:
Marisa Sharkey
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment